Product Description
Mechanisms of Action: TOP1 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Glioblastoma
Phase 2: Breast Cancer|Gastrointestinal Cancer
Phase 1: Esophageal Cancer|Gastrointestinal Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| CDR0000339607 | P1 |
Completed |
Gastrointestinal Cancer|Esophageal Cancer |
2005-12-01 |
2019-03-21 |
Treatments |
|
| EDOABC-4439-001 | P2 |
Completed |
Breast Cancer |
2007-06-01 |
2019-03-21 |
Treatments |
|
| CDR0000329917 | P2 |
Completed |
Breast Cancer |
2006-04-01 |
2019-03-21 |
Treatments |
|
| EDOAGA-6736-001 | P2 |
Completed |
Gastrointestinal Cancer |
2005-06-01 |
2019-03-21 |
Treatments |
|
| EDOAGL-8725-001 | P3 |
Completed |
Glioblastoma |
None |
2019-03-21 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|